57 completed, 15 terminated, 6 unknown, 1 active not recruiting. 24 Phase 4, 23 Phase 3, 19 Phase 2, 8 Not applicable, 8 Phase 1.
Follow Kaletra: new trials by email Literature Review of Kaletra trials Research Report on Kaletra
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2021-05-01 | 2021-04-26 | |
| Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia | Phase 4 | Unknown | October 6 University | 150 | 2020-10-01 | 2021-03-17 |
| FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals Favipiravir, Lopinavir/ Ritonavir, Favipiravir Placebo - COVID-19 | Phase 2 | Completed | University College, London | 240 | 2020-09-24 | 2022-12-15 |
| Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 Low-dose radiotherapy, Hydroxychloroquine Sulfate, Ritonavir/lopinavir - Pneumonia, Viral | Not applicable | Unknown | Grupo de Investigación Clínica en Oncología Radioterapia | 106 | 2020-06-05 | 2021-07-30 |
| Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Lopinavir/Ritonavir 400 mg/100 mg, Placebo - COVID-19 | Phase 2 | Completed | Vanderbilt University Medical Center | 452 | 2020-06-01 | 2024-02-28 |
| Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 Ultra-Low-dose radiotherapy, ventilatory support with oxygen therapy, Lopinavir/ritonavir - Pneumonia, Viral, Cytokine Storm | Not applicable | Suspended | Fundacion GenesisCare | 15 | 2020-04-21 | 2022-03-29 |
| COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir Lopinavir/ritonavir - Coronavirus Infections, Post-exposure Prophylaxis | Phase 3 | Unknown | Unity Health Toronto | 123 | 2020-04-17 | 2021-12-14 |
| Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers Hydroxychloroquine, Placebo of Hydroxychloroquine, Lopinavir and ritonavir - COVID-19 | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 118 | 2020-04-14 | 2023-03-01 |
| Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir - COVID-19, Favipiravir | Not applicable | Completed | Baqiyatallah Medical Sciences University | 40 | 2020-03-29 | 2020-06-16 |
| LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab - COVID-19, Hospitalized COVID-19 Patients | Phase 1 | Unknown | Lebanese University | 1000 | 2020-03-28 | 2024-02-06 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) Lopinavir/ritonavir, Hydroxychloroquine sulfate - COVID-19 | Phase 2 | Terminated | Asan Medical Center | 65 | 2020-03-11 | 2020-05-27 |
| Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin Lopinavir/ritonavir and ritonavir - AIDS, Tuberculosis | Phase 4 | Terminated | University of Miami | 9 | 2016-02-01 | 2019-05-16 |
| IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children ZDV+3TC+LPV/r - HIV Positive, Malnourished | Phase 4 | Completed | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 52 | 2015-10-26 | 2021-08-12 |
| Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Raltegravir, Lopinavir/Ritonavir - HIV, Pregnancy | Phase 2 / Phase 3 | Terminated | Fundação Bahiana de Infectologia | 33 | 2015-06-01 | 2024-10-15 |
| Early Infant HIV Treatment in Botswana Nevirapine, Kaletra, Lamivudine - HIV, Pediatric AIDS | Phase 2 / Phase 3 | Active not recruiting | Harvard School of Public Health (HSPH) | 67 | 2015-05-04 | 2026-02-23 |
| Test Albuvirtide in Experienced Patients albuvirtide, lopinavir-ritonavir, tenofovir - HIV Infections, AIDS | Phase 3 | Completed | Frontier Biotechnologies Inc. | 418 | 2014-02-19 | 2021-10-06 |
| LAAM-HAART PET Imaging [11c] LAAM, Ritonavir, Efavirenz - Healthy Volunteers | Early Phase 1 | Completed | Washington University School of Medicine | 10 | 2013-08-01 | 2017-12-13 |
| Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir - HIV Infection, Tuberculosis | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 71 | 2013-07-13 | 2018-02-13 |
| Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis TDF/FTC/LPV/r, Placebo - Primary Biliary Cirrhosis | Not applicable | Terminated | University of Alberta | 13 | 2012-06-01 | 2024-11-21 |
| Study of Options for Second-Line Effective Combination Therapy (SELECT) Lopinavir/ritonavir, Raltegravir, Emtricitabine/tenofovir disoproxil fumarate - HIV-1 Infection | Phase 3 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 515 | 2012-03-13 | 2021-08-05 |
Showing 20 of 81. Sign in to see all of them.
HIV Infections (38) · Acquired Immunodeficiency Syndrome (18) · COVID-19 (8) · Tuberculosis (4) · Infections (3) · AIDS Dementia Complex (2) · Coronavirus Infections (2) · Hepatitis C (2) · Malaria (2) · Pneumonia (2) · Pneumonia, Viral (2) · Cognitive Dysfunction (1) · Coinfection (1) · Cytokine Release Syndrome (1) · Disease Progression (1)
Abbott (10) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (3) · Fundacion SEIMC-GESIDA (2) · Germans Trias i Pujol Hospital (2) · Oswaldo Cruz Foundation (2) · ViiV Healthcare (2) · AbbVie (prior sponsor, Abbott) (1) · Allina Health System (1) · Asan Medical Center (1) · Bamrasnaradura Infectious Diseases Institute (1) · Baqiyatallah Medical Sciences University (1) · Cantonal Hospital of St. Gallen (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
United States (30) · Brazil (10) · Spain (10) · Canada (7) · South Africa (7) · Thailand (6) · France (5) · Zimbabwe (5) · Malawi (4) · Uganda (4) · Botswana (3) · Germany (3) · India (3) · Italy (3) · Kenya (3)
Thomas J Podsadecki, MD (2) · Alberto La Rosa, MD (1) · Alberto M La Rosa, MD (1) · Alex L Laursen, MD, DMSc (1) · Alexandre N Barbosa, MD, MSc (1) · Allan R. Tenorio, M.D. (1) · Andrew Mason (1) · Andrew Ratsela, MD (1) · Angel Montero, MD, PhD (1) · Angela DM Kashuba, PharmD (1) · Angela Nilius, MD (1) · Ann C Collier, MD (1) · Avy Violari, MBChB, FCPSA (1) · Avy Violari, MD (1)
PMID 16368644, PMID 17487675, PMID 1750226, PMID 17615254, PMID 19020325, PMID 19474651, PMID 19682100, PMID 20056686, PMID 20074791, PMID 20802298, PMID 20942650, PMID 20942667, PMID 21716078, PMID 21767103, PMID 22029910, PMID 22180523, PMID 22448211, PMID 22627182, PMID 22716976, PMID 22730929, PMID 22879899, PMID 22907572, PMID 23494984, PMID 23764539, PMID 23924639, PMID 24038035, PMID 24135775, PMID 24209829, PMID 24348219, PMID 24352352, PMID 24585398, PMID 24602844, PMID 24614377, PMID 24958908, PMID 25072616, PMID 25222305, PMID 25340778, PMID 25386736, PMID 25416075, PMID 25426808, PMID 25985404, PMID 26023212, PMID 26043884, PMID 26397935, PMID 26424232, PMID 26771662, PMID 26774947, PMID 27143666, PMID 27240787, PMID 27424812
U01AI068632 (3), U01AI068636 (3), 2004 (2), 2008 (2), 2009 (2), 5UM1AI068634 (1), P01HD059454 (1), R01AI062512 (1), R01MH058076 (1)